Takeyoshi Yamashita
Technik-/Wissenschafts-/F&E-Leiter bei KYOWA KIRIN CO. LTD.
Aktive Positionen von Takeyoshi Yamashita
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
| KYOWA KIRIN CO. LTD. | Direktor/Vorstandsmitglied | 01.03.2023 | - |
| Technik-/Wissenschafts-/F&E-Leiter | 01.04.2023 | - | |
| Corporate Officer/Principal | 01.04.2015 | 01.04.2023 | |
| ORCHARD THERAPEUTICS PLC | Direktor/Vorstandsmitglied | 24.01.2024 | - |
Karriereverlauf von Takeyoshi Yamashita
Statistik
International
| Japan | 2 |
| Vereinigtes Königreich | 2 |
Operativ
| Director/Board Member | 2 |
| Chief Tech/Sci/R&D Officer | 1 |
| Corporate Officer/Principal | 1 |
Sektoral
| Health Technology | 3 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| KYOWA KIRIN CO. LTD. | Health Technology |
| Private Unternehmen | 1 |
|---|---|
Orchard Therapeutics Plc
 Orchard Therapeutics Plc Pharmaceuticals: MajorHealth Technology Orchard Therapeutics Plc is a biopharmaceutical company, which engages in discovering, acquiring, developing and commercializing gene therapies for patients with rare disorders. The company focuses on its autologous ex vivo gene therapy approach on three therapeutic rare disease franchise areas: primary immune deficiencies, neurometabolic disorders, and hemoglobinopathies. Its portfolio includes Strimvelis, a commercial-stage gamma retroviral-based product for the treatment of Adenosine deaminase deficiency (ADA-SCID). The company was founded by Nicolas Koebel and Andrea Spezzi in August 2018 and is headquartered in London, the United Kingdom. | Health Technology |
- Börse
- Insiders
- Takeyoshi Yamashita
- Erfahrung
